Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to 0.25.

  • Lineage Cell Therapeutics' Equity Ratio fell 6334.53% to 0.25 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.25, marking a year-over-year decrease of 6334.53%. This contributed to the annual value of 0.69 for FY2024, which is 1027.55% up from last year.
  • As of Q3 2025, Lineage Cell Therapeutics' Equity Ratio stood at 0.25, which was down 6334.53% from 0.53 recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Equity Ratio peaked at 0.93 during Q2 2021, and registered a low of 0.25 during Q3 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' median Equity Ratio value was 0.63 (recorded in 2023), while the average stood at 0.65.
  • Its Equity Ratio has fluctuated over the past 5 years, first soared by 1224.56% in 2022, then tumbled by 6334.53% in 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Equity Ratio (Quarter) stood at 0.53 in 2021, then increased by 12.25% to 0.59 in 2022, then grew by 5.86% to 0.63 in 2023, then rose by 10.28% to 0.69 in 2024, then plummeted by 64.48% to 0.25 in 2025.
  • Its last three reported values are 0.25 in Q3 2025, 0.53 for Q2 2025, and 0.71 during Q1 2025.